Skip to main content

13 Result(s)

within C O Freytes Remove this filter Hematology Remove this filter

and

  1. No Access

    Article

    Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

    Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after al...

    E Klyuchnikov, U Bacher, K Woo Ahn, J Carreras, N M Kröger… in Bone Marrow Transplantation (2016)

  2. No Access

    Article

    Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

    In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (G...

    G L Uy, L J Costa, P N Hari, M-J Zhang, J-X Huang… in Bone Marrow Transplantation (2015)

  3. No Access

    Article

    A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma

    Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factor...

    P Satwani, K W Ahn, J Carreras, H Abdel-Azim, M S Cairo… in Bone Marrow Transplantation (2015)

  4. No Access

    Article

    Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

    We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the Internationa...

    M J Lechowicz, H M Lazarus, J Carreras, G G Laport… in Bone Marrow Transplantation (2014)

  5. No Access

    Article

    Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation

    There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or ...

    C O Freytes, D H Vesole, J LeRademacher, X Zhong, R P Gale… in Bone Marrow Transplantation (2014)

  6. No Access

    Article

    Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma

    We evaluated the effect of acute and chronic GVHD on relapse and survival after allogeneic hematopoietic SCT (HSCT) for multiple myeloma using non-myeloablative conditioning (NMA) and reduced-intensity conditi...

    O Ringdén, S Shrestha, G T da Silva, M-J Zhang… in Bone Marrow Transplantation (2012)

  7. No Access

    Article

    Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?

    Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence af...

    C O Freytes, H M Lazarus in Bone Marrow Transplantation (2009)

  8. No Access

    Article

    Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

    The international staging system (ISS) for multiple myeloma (MM) is a validated alternative to the Durie–Salmon staging system (DSS) for predicting survival at diagnosis. We compared these staging systems for ...

    P N Hari, M-J Zhang, V Roy, W S Pérez, A Bashey, L B To, G Elfenbein… in Leukemia (2009)

  9. No Access

    Article

    Allogeneic hematopoietic cell transplantation for metastatic breast cancer

    We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range...

    N T Ueno, J D Rizzo, T Demirer, Y C Cheng, U Hegenbart… in Bone Marrow Transplantation (2008)

  10. No Access

    Article

    Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit

    Multidrug-resistant pathogens have important effects on clinical outcomes. Antibiotic cycling is one approach to control anti-microbial resistance, but few studies have examined cycling in hematology–oncology ...

    J Cadena, C A Taboada, D S Burgess, J Z Ma, J S Lewis II… in Bone Marrow Transplantation (2007)

  11. No Access

    Article

    Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma

    Diarrhea is a major cause of morbidity and discomfort for patients undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation (APBSCT). There are multiple causes of diarrhea in...

    J I Arango, A Restrepo, D L Schneider, N S Callander… in Bone Marrow Transplantation (2006)

  12. No Access

    Article

    Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial

    The serotonin type-3 (5-HT3) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in effi...

    T Walsh, A K Morris, L M Holle, N Callander, P Bradshaw… in Bone Marrow Transplantation (2004)

  13. No Access

    Article

    Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age

    The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patie...

    D E Reece, C Bredeson, W S Pérez, S Jagannath, M J Zhang… in Bone Marrow Transplantation (2003)